NTRANatera, Inc.
Price
+121%1YEnd-of-day closes, not the intraday tick.
Great business, demanding price
Quality strong, nothing alarming, demanding price, growing in the filings, the market undecided.
We are a diagnostics company with proprietary molecular and bioinformatics technology that we are applying to change disease management worldwide. Our cell-free DNA, or cfDNA, technology combines our novel molecular assays, which reliably measure many informative regions across the genome from samples as small as a single cell, with our statistical algorithms that incorporate data available from the broader scientific community to identify genetic variations covering a wide range of serious conditions with high accuracy and coverage.
In the company’s own words · 10-K filed Feb 27, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Natera, Inc. (NTRA) reported revenue of $753M in Q2 2026 (quarter ended Jun 30, 2026), up 38% from the same quarter a year earlier. That came with net loss of $67M. For the full year FY2025, revenue was $2.31B (+36% year on year) and net income −$208M. Its largest region in Q2 2026 was United States at $739M, 98% of the disclosed total, well ahead of EMEA at 1.2%. The next results filing is expected around Nov 5, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 6, 2026Natera Reports Second Quarter 2026 Financial Results.Earnings release · press release
- Jul 6, 2026On July 1, 2026, Monica Bertagnolli notified the Board of Directors (the “Board”) of Natera, Inc. (“Natera” or the “Company”) of her intention to resign as a member of the Board and any committees of the Board, effective July 1, 2026, due to her new position with the National Academy of Medicine.Director or officer change · Form 8-K
- Jun 16, 2026The Board of Directors (the “Board”) of Natera, Inc., a Delaware corporation (the “Company”) (i) increased the size of the full Board from eleven to twelve members and (ii) appointed Thomas Lynch as a member of the Board, in each case effective as of June 2, 2026.Director or officer change · Form 8-K/A
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Q2 2026 · $752.8MThe company’s own SEC segment disclosure.
- United States$739.5M98%
- EMEA$9.0M1%
- Americas Excluding United States$2.2M0%
- Asia Pacific And Other$2.0M0%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.
Diagnostics & Research
Ranks #12 of 21 by RyuScore